Thrombotic Thrombocytopenic Purpura
Conditions
Keywords
Thrombotic Thrombocytopenic Purpura, TTP, Hematology
Brief summary
The purpose is to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.
Detailed description
With this study we hope to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.
Interventions
DRUGRituximab
Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
Sponsors
Genentech, Inc.
Weill Medical College of Cornell University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients will be included in the trial based on the following criteria: * Patients must have TTP with platelet count \< 100,000/mL and microangiopathic hemolytic anemia which is defined as presence of at 3-10 fragmented red blood cells (schistocytes) per high power filed on the peripheral blood smear. * Either gender, age 17 or older * Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment. * TTP not related to underlying cancer, treatment of cancer or transplantation * New onset TTP, or previously diagnosed TTP with an unmaintained remission for \>12 months. * LDH \>2X upper limit of normal * Prothrombin time (PT), partial thromboplastin time (PTT) normal * Direct antiglobulin test (DAT) negative * Subject has provided written informed consent * Patients who have received up to 3 plasmapheresis.
Exclusion criteria
Patients will be excluded from the trial based on the following criteria: * A diagnosis of AIDS. Patients with HIV infection with absolute CD4 counts \>200/ul and no active, significant opportunistic infection are eligible * Patients with a known hepatitis C infection (HCV) and/or with hepatitis B * Patients receiving pheresis more than once a day * Recent (within 1 year) bone marrow or hematopoietic stem cell transplant * Patient is on calcineurin inhibitors, or is unable to come off them * Acute or chronic disseminated intravascular coagulation (DIC), defined by D-dimers \>8mg/ml and fibrinogen \< 100 mg (0.1g)/dl * A diagnosis of metastatic or non-metastatic malignancy other than basal cell carcinoma. * Malignant hypertension (systolic blood pressure \[BP\] \> 200 mm Hg or a diastolic BP \> 130 mm Hg) * Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment). Eligibility resumes 3 days after delivery * Patients with family history of or a previous diagnosis of congenital TTP * Patients with hemolytic uremic syndrome (HUS) * Patients with sepsis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Failure to maintain the complete response until day 120; Non-protocol treatment for TTP, such as other immunosuppressive agents or splenectomy, reinstitution of plasma exchange within the first 90 days | Four months |
Countries
United States
Outcome results
None listed